Hassan Abolhassani1,2, Asghar Aghamohammadi2, Mingyan Fang1,3,4, Nima Rezaei2, Chongyi Jiang3,4, Xiao Liu3,4, Qiang Pan-Hammarström1, Lennart Hammarström5,6,7. 1. Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. 2. Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children's Medical Center, Tehran University of Medical Sciences, Tehran, Iran. 3. BGI-Shenzhen, Shenzhen, 518083, China. 4. China National GeneBank, BGI-Shenzhen, Shenzhen, 518120, China. 5. Division of Clinical Immunology, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden. lennart.hammarstrom@ki.se. 6. BGI-Shenzhen, Shenzhen, 518083, China. lennart.hammarstrom@ki.se. 7. China National GeneBank, BGI-Shenzhen, Shenzhen, 518120, China. lennart.hammarstrom@ki.se.
Abstract
PURPOSE: The etiology of 80% of patients with primary antibody deficiency (PAD), the second most common type of human immune system disorder after human immunodeficiency virus infection, is yet unknown. METHODS: Clinical/immunological phenotyping and exome sequencing of a cohort of 126 PAD patients (55.5% male, 95.2% childhood onset) born to predominantly consanguineous parents (82.5%) with unknown genetic defects were performed. The American College of Medical Genetics and Genomics criteria were used for validation of pathogenicity of the variants. RESULTS: This genetic approach and subsequent immunological investigations identified potential disease-causing variants in 86 patients (68.2%); however, 27 of these patients (31.4%) carried autosomal dominant (24.4%) and X-linked (7%) gene defects. This genetic approach led to the identification of new phenotypes in 19 known genes (38 patients) and the discovery of a new genetic defect (CD70 pathogenic variants in 2 patients). Medical implications of a definite genetic diagnosis were reported in ~50% of the patients. CONCLUSION: Due to misclassification of the conventional approach for targeted sequencing, employing next-generation sequencing as a preliminary step of molecular diagnostic approach to patients with PAD is crucial for management and treatment of the patients and their family members.
PURPOSE: The etiology of 80% of patients with primary antibody deficiency (PAD), the second most common type of human immune system disorder after human immunodeficiency virus infection, is yet unknown. METHODS: Clinical/immunological phenotyping and exome sequencing of a cohort of 126 PAD patients (55.5% male, 95.2% childhood onset) born to predominantly consanguineous parents (82.5%) with unknown genetic defects were performed. The American College of Medical Genetics and Genomics criteria were used for validation of pathogenicity of the variants. RESULTS: This genetic approach and subsequent immunological investigations identified potential disease-causing variants in 86 patients (68.2%); however, 27 of these patients (31.4%) carried autosomal dominant (24.4%) and X-linked (7%) gene defects. This genetic approach led to the identification of new phenotypes in 19 known genes (38 patients) and the discovery of a new genetic defect (CD70 pathogenic variants in 2 patients). Medical implications of a definite genetic diagnosis were reported in ~50% of the patients. CONCLUSION: Due to misclassification of the conventional approach for targeted sequencing, employing next-generation sequencing as a preliminary step of molecular diagnostic approach to patients with PAD is crucial for management and treatment of the patients and their family members.
Authors: Hillary Hernandez-Trujillo; Jordan S Orange; Jason A Roy; Yanli Wang; Craig N Newcomb; Qing Liu; Sean Hennessy; Vincent Lo Re Journal: J Clin Immunol Date: 2015-08-14 Impact factor: 8.317
Authors: Hui Yu; Victor Wei Zhang; Asbjørg Stray-Pedersen; Imelda Celine Hanson; Lisa R Forbes; M Teresa de la Morena; Ivan K Chinn; Elizabeth Gorman; Nancy J Mendelsohn; Tamara Pozos; Wojciech Wiszniewski; Sarah K Nicholas; Anne B Yates; Lindsey E Moore; Knut Erik Berge; Hanne Sorte; Diana K Bayer; Daifulah ALZahrani; Raif S Geha; Yanming Feng; Guoli Wang; Jordan S Orange; James R Lupski; Jing Wang; Lee-Jun Wong Journal: J Allergy Clin Immunol Date: 2016-07-12 Impact factor: 10.793
Authors: Paola G Bronson; Diana Chang; Tushar Bhangale; Michael F Seldin; Ward Ortmann; Ricardo C Ferreira; Elena Urcelay; Luis Fernández Pereira; Javier Martin; Alessandro Plebani; Vassilios Lougaris; Vanda Friman; Tomáš Freiberger; Jiri Litzman; Vojtech Thon; Qiang Pan-Hammarström; Lennart Hammarström; Robert R Graham; Timothy W Behrens Journal: Nat Genet Date: 2016-10-10 Impact factor: 38.330
Authors: Hemmo A F Yska; Kim Elsink; Taco W Kuijpers; Geert W J Frederix; Mariëlle E van Gijn; Joris M van Montfrans Journal: J Clin Immunol Date: 2019-06-28 Impact factor: 8.317